USP37 counteracts HLTF to protect damaged replication forks and promote survival of BRCA1-deficient cells and PARP inhibitor resistance
Nucleic Acids Research · 2025
DOI: 10.1093/nar/gkaf544 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2025. Verfasst von Mengfan Tang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China. Hauptthemen laut MEDLINE: BRCA1 Protein, Poly(ADP-ribose) Polymerase Inhibitors, Drug Resistance, Neoplasm, DNA Replication. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Natural Science Foundation of China, NIH HHS.
Abstract (Originalsprache)
Poly(ADP-ribose) polymerase inhibitors (PARPi) have greatly improved survival of cancer patients harboring BRCA1 mutations. However, therapy resistance develops via either restoration of homologous recombination or replication fork stabilization. Therapeutic targets to overcome PARPi resistance are critically needed. We identified the deubiquitinase USP37 as a key determinant of PARPi toxicity in BRCA1-deficient cells via whole-genome CRISPR screens. USP37 ablation enhanced PARPi sensitivity in BRCA1-deficient cells and also overcame PARPi resistance due to 53BP1 loss. USP37 interacts with and deubiquitinates replication protein A (RPA) at stalled replication forks to limit excessive RPA accumulation, progressive RPA exhaustion, and the conversion of RPA-coated single-stranded DNAs to DNA double-strand breaks. Moreover, USP37 limits helicase-like transcription factor (HLTF) accumulation at replication forks and thus prevents MRE11-dependent fork degradation upon replication stress. Depletion of HLTF reversed the replication-associated damage observed in USP37 knockout cells. Our data suggest that USP37 protects replication fork stability by counteracting HLTF function and promotes survival of BRCA1-deficient cells, making it a promising drug target to overcome PARPi resistance in BRCA1-deficient tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Immunology, School of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
- Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
- Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Pancreas Institute, Nanjing Medical University, Nanjing 210000, China.
- Department of General Surgery, First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China.
ORCID-Profile: Huimin Zhang, Junjie Chen
Förderung
- NCI NIH HHS
- National Natural Science Foundation of China
- NIH HHS
- Jiangsu Specially Appointed Professorship Foundation
- Natural Science Foundation of Jiangsu Province of China
- CPRIT
- Pamela and Wayne Garrison Distinguished Chair in Cancer Research
- NIH
Zitieren
APA
Tang, M., Li, S., Zhu, Z., Wang, C., Ding, S., Zhang, H., Huang, M., Keast, S., Chen, Z., Yin, L., Nie, L., Su, D., Feng, X., & Chen, J. (2025). USP37 counteracts HLTF to protect damaged replication forks and promote survival of BRCA1-deficient cells and PARP inhibitor resistance. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaf544
Vancouver
Tang M, Li S, Zhu Z, Wang C, Ding S, Zhang H, et al. USP37 counteracts HLTF to protect damaged replication forks and promote survival of BRCA1-deficient cells and PARP inhibitor resistance. Nucleic Acids Research. 2025. doi:10.1093/nar/gkaf544
BibTeX
@article{Tang2025,
author = {Tang, Mengfan and Li, Siting and Zhu, Ziqiang and Wang, Chao and Ding, Shuai and Zhang, Huimin and Huang, Min and Keast, Sarah and Chen, Zhen and Yin, Ling and Nie, Litong and Su, Dan and Feng, Xu and Chen, Junjie},
title = {USP37 counteracts HLTF to protect damaged replication forks and promote survival of BRCA1-deficient cells and PARP inhibitor resistance},
journal = {Nucleic Acids Research},
year = {2025},
doi = {10.1093/nar/gkaf544}
}
EUVIMED